• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UCB announces CEO succession plan

UCB announces CEO succession plan

February 24, 2014
CenterWatch Staff

UCB, a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions for the immune system and of the central nervous system, and CEO Roch Doliveux have announced the implementation of its CEO succession plan.

Jean-Christophe Tellier, currently UCB’s executive vice president, Biopharma Brands and Solutions, will be appointed CEO-elect and chairman of the Executive Committee as of March 1. Jean-Christophe Tellier also will be proposed to be appointed as a member of the board at the next Annual General Meeting of Shareholders on April 24.

This change is the result of a long and well thought through succession plan to ensure necessary experience and knowledge transfer. It creates the best conditions for the company’s future growth allowing it, together with its 8500 colleagues, to deliver on UCB’s commitment to patients.

“In the last 10 years, under Roch Doliveux’s leadership, UCB has evolved from a diversified chemical company into a global biopharmaceutical leader,” said Gerhard Mayr, chairman of UCB’s board. “Roch has put everything in place to prepare UCB for its next phase. We are confident that Jean-Christophe Tellier will continue to drive UCB to provide superior and sustainable value for patients. He and Roch will continue to work together throughout 2014 to ensure a smooth handover before Jean-Christophe takes the helm of UCB as of Jan. 1, 2015.”

Roch Doliveux, CEO of UCB, said, “UCB is entering an important new growth era: our late-stage pipeline is poised to reach pivotal milestones from the second half of 2014 through mid- 2016. Leadership continuity is critical to ensuring the successful launch of these important products in the severe disease areas of osteoporosis, lupus and epilepsy. Since joining UCB in 2011, Jean-Christophe has played a key role in UCB’s successes, and he has been instrumental in helping establish our current strategy. Jean-Christophe’s 25-year career in the biopharmaceutical industry, his patient-centric approach, his medical background as a rheumatologist and his passion for developing talent make him the perfect candidate to lead the company through its next phase of evolution.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing